Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Targeting Nucleotide Biosynthesis: A Strategy for Improving the Oncolytic Potential of DNA Viruses.

Irwin CR, Hitt MM, Evans DH.

Front Oncol. 2017 Sep 26;7:229. doi: 10.3389/fonc.2017.00229. eCollection 2017. Review.

2.

Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.

Jhawar SR, Thandoni A, Bommareddy PK, Hassan S, Kohlhapp FJ, Goyal S, Schenkel JM, Silk AW, Zloza A.

Front Oncol. 2017 Sep 11;7:202. doi: 10.3389/fonc.2017.00202. eCollection 2017. Review.

3.

The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.

Khemlina G, Ikeda S, Kurzrock R.

Mol Cancer. 2017 Aug 30;16(1):149. doi: 10.1186/s12943-017-0712-x. Review.

4.

Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.

Futami M, Sato K, Miyazaki K, Suzuki K, Nakamura T, Tojo A.

Mol Ther Oncolytics. 2017 Jul 22;6:57-68. doi: 10.1016/j.omto.2017.07.001. eCollection 2017 Sep 15.

5.

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.

Hamid O, Hoffner B, Gasal E, Hong J, Carvajal RD.

Cancer Immunol Immunother. 2017 Jul 15. doi: 10.1007/s00262-017-2025-8. [Epub ahead of print] Review.

6.

Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy.

Meyers DE, Wang AA, Thirukkumaran CM, Morris DG.

Front Oncol. 2017 Jun 6;7:114. doi: 10.3389/fonc.2017.00114. eCollection 2017. Review.

7.

Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.

Haddad D.

Front Oncol. 2017 May 23;7:96. doi: 10.3389/fonc.2017.00096. eCollection 2017. Review.

8.

Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.

Sanchala DS, Bhatt LK, Prabhavalkar KS.

Front Pharmacol. 2017 May 16;8:270. doi: 10.3389/fphar.2017.00270. eCollection 2017. Review.

9.

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies.

Ahn DH, Bekaii-Saab T.

Biomedicines. 2017 Mar 4;5(1). pii: E10. doi: 10.3390/biomedicines5010010. Review.

10.

Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.

Aitken AS, Roy DG, Bourgeois-Daigneault MC.

Biomedicines. 2017 Jan 4;5(1). pii: E3. doi: 10.3390/biomedicines5010003. Review.

11.

Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.

Yoo SY, Badrinath N, Woo HY, Heo J.

Mediators Inflamm. 2017;2017:5198798. doi: 10.1155/2017/5198798. Epub 2017 Apr 20. Review.

12.

Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes.

Heinrich B, Klein J, Delic M, Goepfert K, Engel V, Geberzahn L, Lusky M, Erbs P, Preville X, Moehler M.

Onco Targets Ther. 2017 May 2;10:2389-2401. doi: 10.2147/OTT.S126320. eCollection 2017.

13.

Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.

Deng L, Fan J, Ding Y, Zhang J, Zhou B, Zhang Y, Huang B.

Oncotarget. 2017 Jun 20;8(25):40533-40543. doi: 10.18632/oncotarget.17125.

14.

Novel oncolytic viral therapies in patients with thoracic malignancies.

Ahmad Z, Kratzke RA.

Oncolytic Virother. 2016 Dec 21;6:1-9. doi: 10.2147/OV.S116012. eCollection 2017. Review.

15.

Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed viral oncotherapy.

Komorowski MP, McGray AR, Kolakowska A, Eng K, Gil M, Opyrchal M, Litwinska B, Nemeth MJ, Odunsi KO, Kozbor D.

Mol Ther Oncolytics. 2016 Dec 14;3:16034. doi: 10.1038/mto.2016.34. eCollection 2016.

16.

Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.

Lee NH, Kim M, Oh SY, Kim SG, Kwon HC, Hwang TH.

Oncotarget. 2017 Jan 3;8(1):1213-1225. doi: 10.18632/oncotarget.13598.

17.

Nanomedicines for renal disease: current status and future applications.

Kamaly N, He JC, Ausiello DA, Farokhzad OC.

Nat Rev Nephrol. 2016 Dec;12(12):738-753. doi: 10.1038/nrneph.2016.156. Epub 2016 Oct 31. Review.

18.

Engineering of double recombinant vaccinia virus with enhanced oncolytic potential for solid tumor virotherapy.

Kochneva G, Sivolobova G, Tkacheva A, Grazhdantseva A, Troitskaya O, Nushtaeva A, Tkachenko A, Kuligina E, Richter V, Koval O.

Oncotarget. 2016 Nov 8;7(45):74171-74188. doi: 10.18632/oncotarget.12367.

19.

Viruses as nanomedicine for cancer.

Badrinath N, Heo J, Yoo SY.

Int J Nanomedicine. 2016 Sep 21;11:4835-4847. eCollection 2016. Review.

20.

Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.

Sampath P, Thorne SH.

Oncolytic Virother. 2015 Jun 18;4:75-82. doi: 10.2147/OV.S54738. eCollection 2015. Review.

Supplemental Content

Support Center